To explore adverse event reporting in the surgical department through the nurses' experiences and perspectives.
An exploratory, descriptive qualitative study was conducted with a theoretical-methodological orientation of phenomenology.
In-depth interviews were conducted with 15 nurses, followed by an inductive thematic analysis.
Themes include motives for reporting incidents, consequences, feelings and motivational factors. Key facilitators of adverse event reporting were effective communication, knowledge sharing, a non-punitive culture and superior feedback.
The study underscores the importance of supportive organisational culture for reporting, communication and feedback mechanisms, and highlights education and training in enhancing patient safety.
It suggests the need for strategies that foster incident reporting, enhance patient safety and cultivate a supportive organisational culture.
This study provides critical insights into adverse event reporting in surgical departments from nurses' lived experience, leading to two primary impacts: It offers specific solutions to improve adverse event reporting, which is crucial for surgical departments to develop more effective and tailored reporting strategies. The research underscores the importance of an open, supportive culture in healthcare, which is vital for transparent communication and effective reporting, ultimately advancing patient safety.
The study followed the Standards for Reporting Qualitative Research and the Consolidated Criteria for Reporting Qualitative Research guidelines.
No patients or public contribution.
We aimed to prospectively describe incident cardiovascular events among people living with HIV (PLWH) in northern Tanzania. Secondary aims of this study were to understand non-communicable disease care-seeking behaviour and patient preferences for cardiovascular care and education.
A prospective observational study.
This study was conducted at the Majengo HIV Care and Treatment Clinic, an outpatient government-funded clinic in Moshi, Tanzania
Adult patients presenting to an HIV clinic for routine care in northern Tanzania were enrolled from 1 September 2020 to 1 March 2021.
At enrolment, participants completed a survey and a resting 12-lead ECG was obtained. At 6 month follow-up, a repeat survey regarding interim health events and repeat ECG was obtained.
Interim major adverse cardiovascular events (MACE) were defined by: self-reported interim stroke, self-reported hospitalisation for heart failure, self-reported interim myocardial infarction, interim myocardial infarction by ECG criteria (new pathologic Q waves in two contiguous leads) or death due to cardiovascular disease (CVD).
Of 500 enrolled participants, 477 (95.4%) completed 6 month follow-up and 3 (0.6%) died. Over the 6 month follow-up period, 11 MACE occurred (3 strokes, 6 myocardial infarctions, 1 heart failure hospitalisation and 1 cardiovascular death), resulting in an incidence rate of 4.58 MACE per 100 person-years. Of participants completing 6 month follow-up, 31 (6.5%) reported a new non-communicable disease diagnosis, including 23 (4.8%) with a new hypertension diagnosis.
The incidence of MACE among PLWH in Tanzania is high. These findings are an important preliminary step in understanding the landscape of CVD among PLWH in Tanzania and highlight the need for interventions to reduce cardiovascular risk in this population.
Objetivo principal: analizar si tomar la dosis de acenocumarol en ayunas favorece lograr un porcentaje de tiempo en rango terapéutico (TRT) valo-rado como óptimo. Metodología: estudio observacional, analítico. Se enseñó a 122 pacientes anticoagulados con acenocumarol una recomenda-ción del prospecto del medicamento (revisión, 2017): “tomar la dosis diaria lo más alejada de las comidas”. Seguimiento desde abril a octubre de 2018. Para cada paciente, en el control de INR, se registró su valor y si tomaba la dosis en ayunas. Finalizado el seguimiento se calculó su TRT. Resultados principales: en aquellos pacientes con una valoración del TRT igual o mayor al 60 %, la diferencia de proporciones entre los que toma-ban la dosis en ayunas y los que la tomaban con alimentos fue de 0,28 (IC 95 %: 0,09 a 0,44). Estadísticamente significativo, p = 0,004. Conclusión principal: tomar acenocumarol en ayunas favorece obtener un tratamiento anticoagulante valorado como óptimo.